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observational studies also confirmed the indirect protection provided by rota-
virus vaccination in countries where rotavirus vaccination programmes have 
been introduced. France has not yet implemented such a programme. Previously 
reported models in France do not include herd protection, thus underestimat-
ing the effectiveness of vaccination. Our study uses a dynamic transmission 
model to account for herd protection and therefore better predict the effect of 
an oral rotavirus pentavalent vaccination programme in France. Methods: 
We developed a dynamic model to account for susceptibility of rotavirus infec-
tion as a function of both age and the number of previous infections. It was 
parameterized with French data on rotavirus gastro-enteritis (RVGE) incidence 
and age-specific contact rates. We evaluated the direct and indirect effects of 
vaccination on disease incidence and clinical outcomes. A three-dose vaccine 
course was assumed to be administered to 75% of infant annually. Results: 
Our model predicts that vaccination can reduce the burden of RVGE by 66% in the 
four years following vaccine introduction, gradually increasing to 73% in the long 
term for children under 5 years of age. Our calculations show that herd immunity 
accounts for 11% to 20% of the overall RVGE reduction in children. Incidence in 
the unvaccinated adult population would also be reduced by more than 40% 
through herd protection. Vaccination is also predicted to reduce pressure on the 
health care system with the model estimating an annual reduction of 84% and 
82% in the number of hospitalization/nosocomial and outpatient visits for RVGE 
respectively. ConClusions: The use of dynamic models is critical to account 
for the indirect effects of rotavirus vaccination via herd protection and thus for 
policymakers to understand the true effectiveness of a country-wide rotavirus 
vaccination programme.
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objeCtives: In Russia free access to high quality health care for patients with 
AIDS and HIV infections guaranteed by state. Some antiretroviral (ARV) pharma-
ceuticals need to be transported and stored in special cold chain conditions that 
significantly increase the burden on the state budget. Use of thermally stable 
formulation if available may be efficient due to fewer expenses for cold chain pro-
vision. To estimate the costs associated with the cold chain conditions in Russian 
health care. Methods: We calculated the difference in costs associated with 
ARV drug lopinavir+ritonavir thermally stable and unstable form transporting 
and storage. Thermally unstable form requires cold chain conditions that drives 
the cost difference. Costs for additional equipment, electricity, staff salaries 
were estimated.We used prices and tariffs that were valid in 2011. Calculations 
were based on the assumption that all eligible registered HIV-infected patients 
in all regions of Russia receive lopinavir+ritonavir, the number of patients was 
extracted from state statistics for 2011with a forecast for 2012. Results: The 
difference in annual total costs of shipping toregional centers and storage till the 
moment patient gets the drug between thermally unstable and thermally stable 
form is 820,000 Euro. ConClusions: Choice of thermally stable form of ARV drug 
lopinavir+ritonavir which do not require cold chain conditions of transportation 
and storage can reduce the economic costs associated with the treatment of HIV 
infection in Russian health care.
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objeCtives: Over the past decades, the number of vaccinations recommended 
for infants has increased significantly, in an effort pursuing wider protection 
against severe infectious diseases. In their first year, infants would typically get 
more than 50 injections. The use of combination vaccines provides one solution 
to the problem of high injection burden but may be undervalued due to the 
underestimation of vaccine-preventable diseases’ seriousness and vaccination 
benefits. Our objective is to investigate the societal value of pediatric combina-
tion vaccines. Methods: A literature search was performed using MEDLINE for 
relevant articles from 1990 to today, focusing on industrialized countries. A grey 
literature search on public health websites was used to complement the peer-
reviewed literature. Results: A total of 86 articles, of which 34 from the peer-
reviewed literature, met the inclusion criteria and were analyzed. Many articles 
presented qualitative argumentation but no quantitative evidence. Public health 
benefits included improved compliance, timeliness and vaccination coverage 
thanks to reduced injections and better acceptability by parents. Economic ben-
efits were linked to the improvement of daily practice efficiency through reduced 
administration burden (less visits, simplified record-keeping, handling, inventory 
management) and less administration-related errors such as the need for fewer 
syringes reducing risk of needle-stick injury. Combination vaccines could also 
enhance efficiency at health care system-level through reduced costs of trans-
port, cold chain, storage and wastage. ConClusions: This review supports the 
broader value of pediatric combination vaccines which may plausibly generate 
time and money savings in the short and longer term, and enhance efficiency at 
both micro and macro levels in the health care system. Findings often stemmed 
from US settings, the portability to other industrialized countries being therefore 
plausible but subject to some uncertainty. While there is a paucity of quantitative 
data to support these arguments, they have significant economic implications 
and warrant further investigation in future economic evaluations of pediatric 
combination vaccines.
to calculate the incremental cost-utility ratio (ICUR) for triple therapy. A subgroup 
analysis was conducted to evaluate cost-effectiveness of TN patients with IL28B 
T/T; Scheuer ≥ 2 and in TE patients with Scheuer ≥ 2. Results: In the overall 
TN population, ICUR is 80917 PLN/QALY (»€ 19736/QALY). ICURs in IL28B T/T and 
Scheuer ≥ 2 subgroups were 42407 PLN/QALY (»€ 10343/QALY) and 86984 PLN/
QALY (»€ 21216/QALY), respectively. In the overall TE population, ICUR is 81793 
PLN/QALY (»€ 19950/QALY). For Scheuer ≥ 2 subgroup ICUR = 72448 PLN/QALY 
(»€ 17670/QALY). Calculated values are below the cost-effectiveness threshold of 
105801 PLN/QALY (»€ 25805/QALY) in Poland. Results for relapsers, partial respond-
ers and null responders are also presented. ConClusions: Based on the cost-
utility analysis, telaprevir combination therapy is cost-effective compared to PR 
alone in Polish settings.
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objeCtives: To estimate the cost difference between use and absence of use of 
Step-Down Strategy (SDS) with linezolid for treatment of nosocomial pneumonia 
(NP) caused by Gram Positive Bacteria (GPB) in Mexico, from public health care 
institution perspective. Methods: To evaluate the potential cost savings between 
the two strategies, a microcosting was made along three phases: (1) characteriza-
tion of therapeutic protocol, (2) assessment of resources and (3) estimation of the 
unit costs of medical care. The temporal horizon of the analysis was set to 14 days. 
Costs were estimated for the year 2013, expressed in US$ and consider the follow-
ing medical services: days of hospitalization, consultation with specialists, route of 
administration, laboratory and imaging tests as well as outpatient control, based 
on unit costs by level of care reported by Instituto Mexicano del Seguro Social. The 
frequency of use of these resources were determined from Delphi method with 
a panel of 10 experienced infectologists. We calculated the differences between 
average total costs (ATC). The stastistical significance difference between strate-
gies was evaluated by Student’s t statistic. Results: The ATC of patients using 
SDS was $10,116, [95%CI $9,344.6 - $10,887.3] and the ATC of patients not using 
this strategy was $17,251.6 [$16,379.4 - $18,123.8]. The average potential savings 
due the use of SDS over conventional therapy (only intravenous) are $ 7,135.6, 
(p< 0.001). ConClusions: The use of step down strategy could significantly 
reduce the costs of treatment of NP in terms of hospitalization, physician visits, 
laboratory and imaging tests, and drug administration, not as well the resources 
used in the outpatient control. In a challenging setting of cost containment poli-
cies, the use of step down strategy in suitable patients represents the opportunity 
to invest health care resources in a more efficient way.
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objeCtives: Vancomycin and linezolid are amongst the most commonly pre-
scribed antibiotics for hospital-acquired infections in China. The aim of this study 
is to estimate and compare the baseline characteristics, hospitalization costs, 
length of stay (LOS), length of therapy (LOT) and all-cause in-hospital mortality 
of patients treated with vancomycin or linezolid. Methods: Data were extracted 
from the electronic medical records (EMR) of a tertiary hospital in Shanghai (bed 
size 1700). The analysis included patients admitted for any underlying cause 
who received either vancomycin or linezolid between January 2009 and July 2012. 
Continuous variables were compared with t test and chi-square for categorical 
variables. Results: Of the total 3234 patients identified, 93.6% were treated with 
vancomycin (female: 40.6%, mean age: 55.8 years) and 6.4% were treated with 
linezolid (female: 22.2%, mean age: 62.3 years). Cardiac Surgery was the most 
frequent admitting department for the both groups, while cardiovascular disease 
was the top admission reason for the vancomycin group and pulmonary infec-
tion for the linezolid group. The average daily dose was 1.6±1.1 g for vancomycin 
and 1.2±0.5 g for linezolid. The all-cause in-hospital mortality was lower in the 
vancomycin group compared to the linezolid group (4.2% vs. 21.7%, p< 0.001). The 
vancomycin group had shorter LOS and LOT compared to the linezolid group 
(23.6±24.4 vs. 37.1±40.8 days, p< 0.001; 7.0±8.8 vs. 8.7±10.6 days, p= 0.025). The van-
comycin group had lower total hospitalization costs, medication costs and antibi-
otics costs compared to the linezolid group (RMB 68788±64956 vs. 125425±117055, 
p< 0.001; 33258±39792 vs. 70372±69115, p< 0.001; 15206±18957 vs. 34681±33184, 
p< 0.001). ConClusions: Vancomycin was more frequently prescribed than lin-
ezolid and was more likely to be used in females and younger patients. When 
compared to those patients treated with linezolid, vancomycin treatment was 
associated with a shorter LOS and LOT, decreased total hospitalization costs and 
decreased total medication and antibiotics costs.
PIN110
whAt ClINICAl beNefIts CoUld be exPeCted from the ImPlemeNtAtIoN 
of A rotAvIrUs vACCINAtIoN ProgrAmme IN frANCe?
Yamin D.1, Remy V.2, Atkins K.E.1, Galvani A.P.1
1Yale University, New Haven, CT, USA, 2Sanofi Pasteur MSD, Lyon, France
objeCtives: Rotavirus vaccines have shown great potential for reducing the 
disease burden of the major cause of severe childhood gastroenteritis. Real-life 
